SCHEMBL8525658

SCHEMBL8525658

Cc1cc(I)no1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5728 0.77
Ammonia Solution, Strong SCHEMBL7395872 0.74
Formaldehyde SCHEMBL27843442 0.70
SCHEMBL2124100 0.69
Boric Acid SCHEMBL28790057 0.69 HCAR2 (0.45)
SCHEMBL15009336 0.69 TRPM8 (0.40)
SCHEMBL20195808 0.69
SCHEMBL1904543 0.69 HCAR2 (0.45)
SCHEMBL20375530 0.69
SCHEMBL12824587 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108129411-A The preparation method of Parecoxib Sodium intermediate 5- methyl -3,4- hexichol isoxazoles 北京沃邦医药科技有限公司 2018-06-08 CN claimed
US-11690911-B2 Combination of ATR kinase inhibitors and PD-1/PD-L1 inhibitors BAYER AKTIENGESELLSCHAFT (DE) 2023-07-04 US disclosed
US-11660301-B2 Combination of ATR kinase inhibitors with PARP inhibitors BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2023-05-30 US disclosed
US-20230015617-A1 PHTHALAZINONE DERIVATIVES KUDOS PHARMACEUTICALS LIMITED (GB) 2023-01-19 US disclosed
WO-2022133529-A1 HETEROCYCLIC INHIBITORS OF PCSK9 Cardio Therapeutics Pty Ltd (AU) 2022-06-30 WO disclosed
EP-3572402-B1 LINKED CYCLIC COMPOUND AS CASPASE INHIBITOR CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) 2022-05-04 EP disclosed
WO-2022053803-A1 HERBICIDAL PYRIMIDINE DERIVATIVES MOA Technology Limited (GB) 2022-03-17 WO disclosed
US-20210369724-A1 COMBINATION OF ATR KINASE INHIBITORS WITH 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE COMPOUNDS BAYER AKTIENGESELLSCHAFT (DE) 2021-12-02 US disclosed
US-11160803-B2 Phthalazinone derivatives KUDOS PHARMACEUTICALS LIMITED (GB) 2021-11-02 US disclosed
EP-3689871-B1 4,6,7-TRISUBSTITUTED 1,2-DIHYDROPYRROL[3,4-C]PYRIDIN/PYRIMIDIN-3-ONE DERIVATIVE AND USE SHANGHAI HAIYAN PHARMACEUTICAL TECH CO LTD (CN) 2021-09-29 EP disclosed
EP-1910385-B1 BENZOTHIAZOLES AND THIAZOLOPYRIDINES AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS INC (US) 2013-07-24 EP disclosed
WO-2012083164-A1 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2012-06-21 WO disclosed
WO-2012083170-A1 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2012-06-21 WO disclosed
EP-2455376-A1 Heterocyclic compounds as inhibitors of hepatitis C virus (HCV) Abbott Laboratories (US) 2012-05-23 EP disclosed
EP-2010289-B1 BENZOAZEPIN-OXY-ACETIC ACID DERIVATIVES AS PPAR-DELTA AGONISTS USED FOR THE INCREASE OF HDL-C, LOWER LDL-C AND LOWER CHOLESTEROL JANSSEN PHARMACEUTICA NV (BE) 2011-11-30 EP disclosed
EP-2368890-A1 Hepatitis C virus inhibitors Abbott Laboratories (US) 2011-09-28 EP disclosed
US-8017635-B2 Phenylalkyl substituted heteroaryl derivatives FMC CORPORATION (US) 2011-09-13 US disclosed
WO-2010144646-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2010-12-16 WO disclosed
WO-2010120935-A1 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2010-10-21 WO disclosed
US-20100152045-A1 Phenylalkyl Substituted Heteroaryl Derivatives FMC CORPORATION 2010-06-17 US disclosed